Teledyne Dalsa has acquired the Sigmascreening B.V. patents and IP portfolio on pressure-sensitive breast compression for screening

Amsterdam, 15 November 2022 – Teledyne DALSA, a Teledyne Technologies company and global leader in Digital X-Ray Image Sensing technology, is pleased to announce it has acquired the Sigmascreening B.V. patents and IP portfolio on pressure-sensitive breast compression for screening. With its purchase, Teledyne DALSA has exclusive access to the Sigmascreening IP portfolio and algorithms. Holland Capital was one of the early investors in Sigmascreening.

Unique combination
The unique combination of detector and pressure-sensitive compression is expected to create new possibilities for immediate diagnostic information as well as biomarkers for breast screening. According to Thorsten Achterkirchen, Vice President and General Manager of Teledyne DALSA’s X-Ray Solutions business, “We intend to expand our CMOS X-Ray detector product line for mammography and digital breast tomosynthesis (DBT) with new subsystem products for optimizing breast imaging and improving patient comfort during mammographic screening.”

Ivo Aarninkhof, CEO of Sigmascreening, says that ‘’We are delighted with the purchase of the Sigmascreening patents and IP portfolio by Teledyne DALSA. Use of the pressure-based compression during digital breast tomosynthesis and mammography improves participant and technologist experience and reduces compression pressure variability, mean breast thickness, and glandular dose.”¹

Expertise in radiology
Holland Capital joined the company in 2014 as an early investor. The investment has been used for product development and commercial growth in recent years. Holland Capital is experienced in supporting innovative radiology solutions. This is the investor’s second exit in the field of medical imaging, following the acquisition of Quantib, a leading radiology artificial intelligence (“AI”) company, by RadNet Inc earlier this year.

Jan-Frens van Giessel, Partner Holland Capital : “We are proud that we have been able to assist Sigmascreening in the past 8 years. Sigmascreening’s pressure sensitive breast compression reduces extreme pain during mammography and improves detection of breast cancer. It is great to see that this important healthcare innovation will become available for women worldwide with the acquisition of Teledyne DALSA.”

About Teledyne DALSA
Teledyne DALSA provides state-of-the-art image sensing, capture and processing solutions to medical, dental, and scientific equipment manufacturers. Building on more than 30 years of proven capability and innovation, our highly skilled team of imaging specialists adds value with their continued focus on leading-edge product design. Our manufacturing processes are tailored to comply with the stringent quality, reliability, and traceability requirements of the medical and scientific X-ray community.

About Sigmascreening
Sigmascreening B.V. is a medical device company focusing on the development of new innovative products in the area of digital mammography and breast cancer screening. Sigmascreening was established as a spin-off company from the Amsterdam UMC.

About Holland Capital
Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 150 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team understand entrepreneurship. They aim to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful Healthcare and Technology entrepreneurs.

¹ quote is based on this scientific article: https://academic.oup.com/jbi/advance-article/doi/10.1093/jbi/wbaa070/5902745

AMP Group and 2MC join forces

Amsterdam/Houten, 14 November 2022 – Our portfolio company AMP Group joins forces with medical logistics company 2MC. By working together, which in part has been made possible by Holland Capital, the organization is significantly expanding its position in the medical logistics market. With 2MC, AMP Group is taking its third step in its buy-and-build strategy.

2MC
2MC specialises in transporting diagnostic material (e.g. blood, tissues, smear tests) from general practitioners and other medical institutions to laboratories throughout the Netherlands. The company provides transport for pathology, medical microbiology and clinical chemistry. 2MC also transports Covid-19 samples from test locations to laboratories and supplies Covid-19 vaccines and test materials.

The medical logistics market
AMP Group is fully committed to the safe and refrigerated delivery of medicines and valuable products where strict safety requirements, such as identification, must be met. The collaboration with 2MC is the third acquisition in AMP Group’s buy-and-build strategy. Late 2021, AMP Group and Delta Logistics started their collaboration, Delta Logistics is a large independent logistics B2B solutions provider, specialized in active refrigerated delivery of pharmaceutical and veterinary products throughout the Netherlands. Mid 2022, Omega Logistics was acquired by AMP Group. Omega Logistics is a specialized logistics service provider that operates mainly in the pharmaceutical and healthcare sector. With these three acquisitions, AMP Group has attained a leading position in the rapidly growing medical logistics market (B2B and B2C).

Marco van der Klij, Managing Director of AMP Group: “By joining forces with 2MC, we as a group can continue to broaden our logistics services within the medical market. The logistics for diagnostic material are usually arranged in such a way that the collected samples can be processed by the laboratory on the same day. With 2MC on board, we now also have a solution for this. We also see opportunities to use these services for non-medical laboratories.”

Ruud Koreman, General Manager of 2MC: “We have been looking for opportunities to expand in the medical transport segment, for both B2B and B2C.  We have found a strong partner in AMP Group with whom we can realize our growth ambitions. We look forward to leveraging the new opportunities that this collaboration will open up for veterinary and non-medical labs.”

Holland Capital has been actively involved as a shareholder in AMP Group since the end of 2020.

About 2MC
For over twenty years, 2MC has specialized in transporting diagnostic material between medical institutions and laboratories. The organization arranges, among other things, the logistics for the cervical cancer population screening throughout the Netherlands. Fragile materials, such as the Covid-19 vaccines, are transported in a temperature-controlled vehicle, which is either cooled or at room temperature. 2MC offers easy and interesting work for pensioners, who usually find this courier work a nice way to contribute to society while earning some extra money.

About AMP Group
Over the past twenty years, AMP Group has grown from a start-up to a mature company that works for leading customers such as T-Mobile, KPN, Kiwa, ABN-AMRO, International Card Services, hospitals, pharmacies, medical wholesalers and over sixty municipalities. Among other services, AMP Group delivers medicines, telephones and confidential documents that require recipient identification. In addition to its proprietary customer experience and route planning software, the company uses the latest technology in ID authentication, facial recognition and biometric signatures to accurately identify the recipient.

About Holland Capital
Holland Capital has invested responsibly and successfully in more than 150 Dutch SMEs over the past 40 years. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team understand entrepreneurship. They aim to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful Healthcare and Technology entrepreneurs.

Defibrion acquires DefibSolutions and expands its business

Amsterdam, 1 November 2022 – Our portfolio company Defibrion acquires DefibSolutions, a wholesaler of AEDs and resuscitation products. By joining forces, Defibrion strengthens its market position in AEDs and related products & services in the field of emergency response. The acquisition was supported by Holland Capital.

 Increasing importance of preventative care and safety devices due to an aging population
In an aging society, the importance of preventative care- and safety devices in the workplace and in public spaces increases dramatically. The increased demand for AEDs, has led to a high “AED density” in the Netherlands. In neighbouring countries, this development has begun as well and Defibrion expects to contribute significantly to the increase of AEDs in public- and commercial buildings.

As a supplier of AEDs and emergency response products and services, Defibrion is a fast-growing player. Customers can rely on the company for safety products, services and advice. Defibrion  dominates in the Benelux with its services and is active throughout Europe with its products. Activities in North America have also increased in recent years.

Joining forces
In partnership with DefibSolutions, Defibrion is able to serve its European customer base with a broader product portfolio. In addition, it offers both companies the opportunity to increase its customer base in  markets where both companies operate.

Joshua Valkenier, CEO Defibrion: “DefibSolutions complements our plans to offer a broader product portfolio to our distributors in Europe. The organisation, focus and products fit well with Defibrion’s business and will help us to respond to increasing demands from international markets.”

Edwin Roelse, CEO DefibSolutions: “By taking this step, we have a unique opportunity to continue growing together and broaden our product range within a significantly larger region. I have always been in favour of seeking out collaborations and this step is unparalleled.”

Holland Capital has been involved as a shareholder in Defibrion since 2019. It actively supports management in the strategic development of the company.

About DefibSolutions
DefibSolutions, founded in 2016, is a wholesaler of AEDs and other resuscitation related products and mainly supplies to resellers in Europe. DefibSolutions offers a broad product portfolio, but has been a European partner since 2019 and thus importer of ZOLL International, manufacturer of ZOLL AEDs. Within the Netherlands, DefibSolutions also operates as BHV Voordeelwinkel.nl.

About Defibrion
Defibrion was founded in 2008 and offers a wide range of AEDs and emergency response equipment in Europe. In the Benelux they are the exclusive importer of HeartSine AEDs and offer a full-service concept, including installation, advice, maintenance and training. In addition, Defibrion has developed its own AED cabinet series, operating under the name ARKY, which is sold in over 30 countries worldwide.

About Holland Capital
Holland Capital has invested responsibly and successfully in more than 150 Dutch SMEs over the past 40 years. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team understand entrepreneurship. They aim to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful Healthcare and Technology entrepreneurs.